prikaz prve stranice dokumenta Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
  Preuzmi
PDF 9.93 MB
Znanstveni rad - Prethodno/kratko priopćenje
Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
International Journal of Molecular Sciences, 24 (2023); 1-25. https://doi.org/10.3390/ijms241612906
Car, Iris; Dittmann, Antje; Vasieva, Olga; Bočkor, Luka; Grbčić, Petra; Piteša, Nikolina; Klobučar, Marko; Kraljević Pavelić, Sandra; Sedić, Mirela

Citirajte ovaj rad

Car, I., Dittmann, A., Vasieva, O., Bočkor, L., Grbčić, P., Piteša, N. ... Sedić, M. (2023). Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro. International Journal of Molecular Sciences, 24., 1-25. doi: 10.3390/ijms241612906

Car, Iris, et al. "Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro." International Journal of Molecular Sciences, vol. 24, 2023, str. 1-25. https://doi.org/10.3390/ijms241612906

Car, Iris, Antje Dittmann, Olga Vasieva, Luka Bočkor, Petra Grbčić, Nikolina Piteša, Marko Klobučar, Sandra Kraljević Pavelić i Mirela Sedić. "Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro." International Journal of Molecular Sciences 24 (2023): 1-25. https://doi.org/10.3390/ijms241612906

Car, I., et al. (2023) 'Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro', International Journal of Molecular Sciences, 24, str. 1-25. doi: 10.3390/ijms241612906

Car I, Dittmann A, Vasieva O, Bočkor L, Grbčić P, Piteša N, i sur.. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro. International Journal of Molecular Sciences [Internet]. 17.08.2023. [pristupljeno 03.05.2024.];24:1-25. doi: 10.3390/ijms241612906

I. Car, et al., "Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro", International Journal of Molecular Sciences, vol. 24, str. 1-25, Kolovoz 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:018325. [Citirano: 03.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:018325
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
AutorIris Car
AutorAntje Dittmann
AutorOlga Vasieva
AutorLuka Bočkor
AutorPetra Grbčić
AutorNikolina Piteša
AutorMarko Klobučar
AutorSandra Kraljević Pavelić
AutorMirela Sedić
Autorova ustanovaSveučilište u Rijeci
Fakultet zdravstvenih studija
(Katedra za temeljne medicinske znanosti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Genetika, genomika i proteomika čovjeka
Sažetak (engleski)
Despite the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facilitate the design of novel pharmacological strategies for BRAF-mutated mCRC. The aim of this study was to identify novel protein candidates involved in acquired resistance to BRAFV600E inhibitor vemurafenib in BRAFV600E-mutated colon cancer cells using an integrated proteomics approach. Bioinformatic analysis of obtained proteomics data indicated actin-cytoskeleton linker protein ezrin as a highly ranked protein significantly associated with vemurafenib resistance whose overexpression in the resistant cells was additionally confirmed at the gene and protein level. Ezrin inhibition by NSC305787 increased anti-proliferative and pro-apoptotic effects of vemurafenib in the resistant cells in an additive manner, which was accompanied by downregulation of CD44 expression and inhibition of AKT/c-Myc activities. We also detected an increased ezrin expression in vemurafenib-resistant melanoma cells harbouring the BRAFV600E mutation. Importantly, ezrin inhibition potentiated anti-proliferative and pro-apoptotic effects of vemurafenib in the resistant melanoma cells in a synergistic manner. Altogether, our study suggests a role of ezrin in acquired resistance to vemurafenib in colon cancer and melanoma cells carrying the BRAFV600E mutation and supports further pre-clinical and clinical studies to explore the benefits of combined BRAF inhibitors and actin-targeting drugs as a potential therapeutic approach for BRAFV600E-mutated cancers.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prethodno/kratko priopćenje
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaInternational Journal of Molecular Sciences
Brojčani podacivol. 24, str. 1-25
p-ISSN1661-6596
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms241612906
URN:NBNurn:nbn:hr:184:018325
Datum objave publikacije2023-08-17
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-08-21 06:40:23